路透香港8月12日 - 中国药物和新材料AI研发平台--晶泰控股2228.HK：
* 预期截至2025年中期期间之本集团综合收益将不少于5亿元人民币，按年增加至少约387%
* 预期将转亏为盈，由2024年中期经调整亏损净额（非国际财务报告准则计量）2.51396亿元转为2025年中期经调整纯利不少于1.2亿元；这是本集团首次实现半年盈利
公告全文，请点击此处
(Reporting By Alison Lui)
((alison.lui@thomsonreuters.com; +852 3462 7749;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.